The estimated Net Worth of Mark M Sieczkarek is at least $94.2 mil dollars as of 3 March 2015. Mark Sieczkarek owns over 166,666 units of Novabay Pharmaceuticals Inc stock worth over $94,166 and over the last 11 years Mark sold NBY stock worth over $0.
Mark has made over 3 trades of the Novabay Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Mark bought 166,666 units of NBY stock worth $100,000 on 3 March 2015.
The largest trade Mark's ever made was buying 166,666 units of Novabay Pharmaceuticals Inc stock on 3 March 2015 worth over $100,000. On average, Mark trades about 9,356 units every 14 days since 2014. As of 3 March 2015 Mark still owns at least 196,466 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Mark Sieczkarek stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... y Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: